Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05704634 · ClinicalTrials.gov registry record · Phase 1

A Phase Ib Study to Evaluate the Safety and Preliminary Efficacy of IL6-receptor Antibody Sarilumab in Combination With antiPD1 Antibody Cemiplimab for Patients With Non-small Cell Lung Cancer.

A Phase 1 study of Lung Cancer, sponsored by M.D. Anderson Cancer Center.

Active
Registry status
Phase 1
Development phase
56
Enrollment target
1
Study location

NCT05704634: Active Phase 1 study of Lung Cancer, sponsored by M.D. Anderson Cancer Center.

NCT05704634 is a Phase 1 study of Lung Cancer that is active but no longer recruiting, run by M.D. Anderson Cancer Center. The registered enrollment target is 56 participants, below the 936-participant average among 409 other Lung Cancer trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05704634, a Phase 1 study of Lung Cancer, is active but no longer recruiting, sponsored by M.D. Anderson Cancer Center.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
56 participants
Enrollment target
1
Study location

Study Summary

To learn if the combination of sarilumab (also called Kevzara) and cemiplimab can help to control EGFR- or LKB1/STK11-mutant NSCLC.

Conditions Studied

Lung Cancer

Interventions

  • DRUG Cemiplimab
  • DRUG Kevzara (Sarilumab)

Study Locations (1)

Texas

  • M D Anderson Cancer Center - Houston

Trial Details

FieldValue
Enrollment Target 56 participants
Start Date 2023-08-18
Est. Completion 2028-01-01
Phase Phase 1

Sponsor

M.D. Anderson Cancer Center

2,692 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05704634

The ClinicalTrials.gov registry entry for NCT05704634 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 56 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 936-participant average among 409 other Lung Cancer trials with a reported enrollment target (94% lower). The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Lung Cancer appearing as the primary indexed condition, and to 2 interventions - of which Cemiplimab is the first listed.

NCT05704634 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.

Frequently Asked Questions

What is clinical trial NCT05704634 about?

NCT05704634 is a clinical study titled "A Phase Ib Study to Evaluate the Safety and Preliminary Efficacy of IL6-receptor Antibody Sarilumab in Combination With antiPD1 Antibody Cemiplimab for Patients With Non-small Cell Lung Cancer.". To learn if the combination of sarilumab (also called Kevzara) and cemiplimab can help to control EGFR- or LKB1/STK11-mutant NSCLC.

What is the current status of trial NCT05704634?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 56 participants. The study started on 2023-08-18. Estimated completion is 2028-01-01.

What conditions does trial NCT05704634 study?

This clinical trial studies the following conditions: Lung Cancer.

What interventions are being tested in trial NCT05704634?

The interventions under investigation include: Cemiplimab (DRUG), Kevzara (Sarilumab) (DRUG).

Who is sponsoring clinical trial NCT05704634?

This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05704634 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Lung Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Lung Cancer

All registered trials for this condition

Texas

All trials with a study site in Texas

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Related

Compare this shortlist side-by-side

Read our methodology - how this data is sourced, computed, and verified.
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.